Abstract Submission

Abstract Presentation Information: If you did not receive additional details of your platform or poster presentation on June 13, please check your junk mail box and then contact us at meetings@cancergenomics.org.
 

2022 CGC Annual Meeting Abstracts
Many thanks to all those who submitted abstracts for CGC 2022.
We received 146 abstracts, a record number of submissions for the CGC.
See below to know where CGC 2022 abstracts originated...


Abstract Submission:
  • Abstracts should represent original scientific research.
  • Abstract submission is for both Oncology and Constitutional topics. Suggested topics are found below. Abstracts will be considered outside these topics.
  • There is a 250 word limit on the text in the body of submitted abstracts.
  • Accepted abstracts will be designated as poster or virtual platform presentations. 
  • All accepted abstracts will be published in Cancer Genetics.
  • Abstracts must be submitted by Monday, February 28, 2022, 11:59 PM (midnight) Pacific Standard Time.
  • Abstract acceptance notifications are expected to be sent on or before April 8, 2022.
  • Presenting authors of accepted abstracts must register and pay for meeting attendance by April 25, 2022 to secure abstract publication in Cancer Genetics. 
  • While in the submission module, if you need to return to a previous page in the submission process, please use the back arrow on your browser.
  • Abstracts are selected based on scientific rigor.
  • Abstracts commercial in nature will not be accepted. Companies who choose to support the meeting have other opportunities to present data about specific products.
  • If you have challenges with your submission, please email meetings@cancergenomics.org.


2022 Abstract Submission Topics:

  • Bioinformatics and Artificial Intelligence
    • Challenges and Approaches in Reporting Results
    • Electronic Health Records and Genomic Data
    • Integration of Genomic Results in the EMR, Instead of Reporting as PDF or Text File Format
  • Genomic Resources for Variant Curation and Standardization
  • Cytogenomic Testing in the Era of Targeted Therapy 
  • Technical Topics (e.g., Assay Validation, Mosaicism, Emerging Technologies, Liquid Biopsy, etc.)
  • Solid Tumors (Testing Algorithms, Cases, and/or Clinical Management)
    • Immunotherapy and Tumor Mutational Burden
  • Hematologic Malignancies (Testing Algorithms, Cases, and/or Clinical Management)
  • Constitutional Disorders (Testing Algorithms, Cases, and/or Clinical Management)
    • Hereditary Cancer Syndromes / Cancer Predisposition
    • Vascular Anomalies and Tissue Overgrowth Syndromes
  • Incidental Findings of Clinical Significance During Genomic Testing
  • Pharmacogenomics (Testing Algorithms, Cases, and/or Clinical Management)
  • Equity (Disparities) in Genomic Testing
  • Regulatory and Ethical Consideration in Genomic Testing
    • Guidelines and Regulatory Compliance 
    • Economic Affairs (e.g., Billing, Coding, Reimbursement)
    • Social and Ethical Considerations
  • Other Oncology and Constitutional Topics 
Please do not hesitate to submit an abstract that does not fit into a category above.
Abstract Presentation Information:
  • If you did not receive additional details of your platform or poster presentation on June 13, please check your junk mail box and then contact us at meetings@cancergenomics.org.